Why Are Cullinan Oncology Shares Rising Today?

  • Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc CGEM lead program, CLN-081/TAS6417.
  • Under the agreement, Taiho will acquire Cullinan Oncology’s subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/TAS6417, for an upfront payment of $275 million and up to an additional $130 million tied to EGFR exon20 non-small cell lung cancer regulatory milestones.
  • Cullinan Oncology will co-develop CLN-081/TAS6417 and retain the option to co-commercialize it in the U.S.
  • Taiho will commercialize CLN-081/TAS6417 in territories outside U.S. and China. 
  • The companies will equally contribute to the future clinical development of CLN-081/TAS6417 in the U.S., with each receiving 50% of the profits from potential U.S. sales. 
  • As a result of the upfront cash payment and reduction in development and pre-commercialization costs, Cullinan Oncology anticipates its cash runway to extend through 2026 (2024 expected earlier) based on current operating plans.
  • At December 31, Cullinan held a cash balance of $430.9 million.
  • Price Action: CGEM shares are up 23.7% at $9.04 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!